Summary of Purpose
Patients presenting with acute cerebral ischemic events are randomly assigned into aspirin (n=40) or cilostazol (n=40) group in a double-blinded manner. FMD is measured as a primary outcome at baseline (T0) and 90 days (T1). Serious and non-serious adverse events were described.Read More →
The following dates are available for this trial. Trial information last updated on 12 April 2017.
|1 Mar 2012||12 Apr 2017||31 Oct 2014||31 Oct 2014||1 Apr 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|